Hepatitis C Virus

Key Points

- The primary mode of hepatitis C transmission in Canada is injection drug use.
- Harm reduction is the main method for hepatitis C prevention in Canada.
- An estimated 332,414 people were antibody positive for hepatitis C in 2011.
- An estimated 220,697 to 245,987 Canadians were living with chronic hepatitis C in 2011.

Hepatitis C is a blood-borne infection caused by the hepatitis C virus. Some people are able to clear the virus from their body soon after they get hepatitis C; however, in about three-quarters of people, the infection becomes chronic. Chronic infection can lead to severe liver damage (cirrhosis), liver cancer and liver failure (which requires a liver transplant). Hepatitis C treatment cures almost everyone. For many people, treatment means taking pills once a day for eight to 12 weeks. People cured of hepatitis C can get hepatitis C again (re-infection).

Hepatitis C is most commonly transmitted when the blood of someone carrying the virus gets into the bloodstream of someone without hepatitis C. The most common way this happens in Canada is through sharing equipment to inject drugs. Since 2000, hepatitis C has been increasingly detected in HIV-positive men who have sex with men. There is increasing evidence that hepatitis C transmission through sexual contact is occurring, especially when blood is present, among HIV-positive gay men.

Harm reduction approaches, such as needle and syringe distribution programs, and condom use, especially among gay men, are the two main prevention approaches for hepatitis C.

Hepatitis C is 10 times more transmissible than HIV through blood contact. However, HIV is more easily transmitted than hepatitis C through sexual contact. There is no vaccine to prevent hepatitis C.

Many people with hepatitis C experience few or no symptoms. This makes it more difficult to ensure timely diagnosis. Because of the shared routes of transmission, it is important that people who have been diagnosed with either HIV or hepatitis C be tested for the other virus and provided with appropriate prevention counselling.

In 2011, an estimated 332,414 people were antibody positive for hepatitis C. This indicates either a current or past infection with hepatitis C. This is the equivalent of 10 people out of every 1,000 Canadians (or 1.0% of the total Canadian population). People who inject drugs (both current and former) comprised 42.6% of all antibody-positive cases. People born in a country outside of Canada comprised an additional 35.0% of all antibody-positive cases.

At the end of 2011, an estimated six to seven in every 1,000 Canadians (0.6% to 0.7%) were living with chronic hepatitis C. This means that as of 2011, there were an estimated 220,697 to 245,987 people in Canada with chronic hepatitis C. Approximately 44% of people with chronic hepatitis C were unaware that they had it.

Resources

Global health sector strategy on viral hepatitis 2016-2021 – World Health Organization

Global Health Sector Strategy on Viral Hepatitis: What does it mean for Canadians? – Prevention in Focus

The epidemiology of hepatitis C in Canada – CATIE fact sheet

Hepatitis C in Canada – CATIE infographic

Hepatitis C in Canada – Public Health Agency of Canada (PHAC) Infographic
Sources

Disclaimer

Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV- and hepatitis C-related illness and the treatments in question.

CATIE provides information resources to help people living with HIV and/or hepatitis C who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible. We strongly urge users to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

CATIE endeavours to provide the most up-to-date and accurate information at the time of publication. However, information changes and users are encouraged to ensure they have the most current information. Users relying solely on this information do so entirely at their own risk. Neither CATIE nor any of its partners or funders, nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. Any opinions expressed herein or in any article or publication accessed or published or provided by CATIE may not reflect the policies or opinions of CATIE or any partners or funders.

Information on safer drug use is presented as a public health service to help people make healthier choices to reduce the spread of HIV, viral hepatitis and other infections. It is not intended to encourage or promote the use or possession of illegal drugs.

Permission to Reproduce

This document is copyrighted. It may be reprinted and distributed in its entirety for non-commercial purposes without prior permission, but permission must be obtained to edit its content. The following credit must appear on any reprint: This information was provided by CATIE (the Canadian AIDS Treatment Information Exchange). For more information, contact CATIE at 1.800.263.1638.

© CATIE

Production of this content has been made possible through a financial contribution from the Public Health Agency of Canada.

Available online at: